>아시아 태평양 헌터 증후군 치료 시장, 심각도(경미~중등도, 중등~중증), 유형(효소 대체 요법(ERT), 줄기세포 이식, 수술적 치료, 기타), 합병증(호흡기 질환, 신경계 질환, 위장 장애, 심혈관, 안과, 청각, 치과, 근골격계, 기타), 최종 사용자(병원, 진료소, 가정 의료, 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국, 기타), 국가(일본, 중국, 호주, 인도, 한국, 싱가포르, 인도네시아, 태국, 말레이시아, 필리핀, 베트남 및 아시아 태평양 지역 기타 지역) 산업 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 아시아 태평양 헌터 증후군 치료 시장
아시아 태평양 헌터 증후군 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 9.1%의 CAGR로 성장하고 있으며 2028년까지 5억 8,792만 달러에 도달할 것으로 예상한다고 분석했습니다. 유전적 유전 질환의 유병률 증가와 유전자 치료 채택 증가는 예측 기간 동안 시장 수요를 촉진한 주요 요인입니다.
헌터 증후군은 효소인 이두로네이트-2-설파 타아제가 없거나 제대로 작동하지 않아 발생하는 희귀한 유전성 질환입니다 . 이로 인해 신체가 신체의 당 분자를 제대로 소화하거나 분해하지 못합니다. 이러한 분자가 시간이 지남에 따라 장기와 조직에 축적되면 신체적, 정신적 발달과 능력에 영향을 미치는 손상을 일으킬 수 있습니다. 이 질환은 거의 항상 소년에게 발생합니다. 이 질환은 점액다당증(MPS)이라고 하는 유전성 대사 장애 그룹의 한 유형입니다.
헌터 증후군은 신체가 신체의 당 분자를 제대로 소화(분해)하지 못하는 희귀한 유전성 질환입니다. 이러한 분자가 시간이 지남에 따라 장기와 조직에 축적되면 신체적, 정신적 발달과 능력에 영향을 미치는 손상을 일으킬 수 있습니다.
증후군과 치료 옵션에 대한 대중의 인식, 의료 인프라 개선, 전 세계 의료 산업 성장을 위한 정부의 투자 증가는 예측 기간 동안 아시아 태평양 헌터 증후군 치료 시장의 성장을 가속화할 가능성이 높습니다. 반면, 유리한 정부 이니셔티브와 기술 발전은 위에서 언급한 예측 기간 동안 헌터 증후군 치료 시장 성장에 엄청난 기회를 가져올 것입니다. 그러나 치료와 관련된 부작용, 병인 부족, 낮은 유병률은 예측 기간 동안 시장 성장을 제한할 것으로 예상되는 요인입니다.
헌터 증후군 치료 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
아시아 태평양 헌터 증후군 치료 시장 범위 및 시장 규모
헌터 증후군 치료 시장은 심각도, 유형, 합병증, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
- 심각도에 따라 아시아 태평양 헌터 증후군 치료 시장은 경증에서 중증, 중증에서 중증으로 세분화됩니다. 2021년에는 신흥 시장과 연구개발에 대한 막대한 투자로 인해 중증에서 중증 세그먼트가 아시아 태평양 헌터 증후군 치료 시장을 지배하고 있습니다.
- 유형에 따라 아시아 태평양 헌터 증후군 치료 시장은 효소 대체 요법(ERT), 줄기 세포 이식, 수술적 치료 및 기타로 세분화됩니다. 2021년에는 효소 대체 요법(ERT)이 얼굴 특징의 거칠기 감소와 관절 운동 범위 개선으로 인해 아시아 태평양 헌터 증후군 치료 시장을 지배하고 있습니다.
- 합병증을 기준으로 아시아 태평양 헌터 증후군 치료 시장은 호흡기 질환, 신경계 질환, 위장 장애, 심혈관 , 안과, 청각, 치과 , 근골격계, 기타로 세분화됩니다. 2021년에는 헌터 증후군의 유병률이 높고 호흡기 질환이 증가함에 따라 호흡기 질환 부문이 아시아 태평양 헌터 증후군 치료 시장을 지배하고 있습니다.
- 최종 사용자를 기준으로 아시아 태평양 헌터 증후군 치료 시장은 병원, 진료소, 홈 헬스케어 및 기타로 세분화됩니다. 2021년에는 병원 부문이 양질의 치료와 적절한 치료로 인해 아시아 태평양 헌터 증후군 치료 시장을 지배하고 있습니다.
- 유통 채널을 기준으로 아시아 태평양 헌터 증후군 치료 시장은 병원 약국, 소매 약국, 온라인 약국 등으로 세분화됩니다. 2021년에는 병원 약국 부문이 같은 기관에서 함께 일하는 약사 팀이 더 많아 아시아 태평양 헌터 증후군 치료 시장을 지배하고 있습니다.
헌터 증후군 치료 시장 국가 수준 분석
헌터 증후군 치료 시장을 분석하고, 심각도, 유형, 합병증, 최종 사용자 및 유통 채널을 기반으로 시장 규모 정보를 제공합니다.
The countries covered in the hunter syndrome treatment market report are the Japan, China, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and rest of Asia-Pacific.
Hospitals segment in Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of innovative R&D and new product launches and approvals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
The Increase in the Cases of Inherited Genetic Disorders among Population across the Globe and Favorable Government Initiatives are Boosting the Market Growth of Hunter Syndrome Treatment Products
Hunter syndrome treatment market also provides you with detailed market analysis for every country growth in hunter syndrome treatment products industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the hunter syndrome treatment market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Hunter Syndrome Treatment Market Share Analysis
Hunter syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to hunter syndrome treatment market.
The major companies operating in the Asia-Pacific hunter syndrome treatment are Pfizer Inc., Takeda Pharmaceutical Company Limited, Medtronic, Abbott, On-X Life Technologies (a subsidiary of CryoLife Inc.), BD, Johnson & Johnson Services, Inc., Stryker, UCB S.A., Novartis AG, JCR Pharmaceuticals Co., Ltd., AVROBIO Inc., Green Cross Corp, CANbridge Life Sciences Ltd., and Medical Device Business Services Inc. among others.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the hunter syndrome treatment market.
For instance,
- 2021년 3월, 어린이 국립 병원과 다케다 제약 회사는 희귀 질환 임상 활동 프로토콜(Rare-CAP) 프로그램을 창설했다고 발표했습니다. 이 프로그램은 희귀 질환 환자의 진단 및 치료 과정을 표준화하는 데 도움이 되는 프로토콜의 개발, 배포 및 큐레이션을 위한 네트워크 시스템을 구축할 것입니다. 이 파트너십은 희귀 질환 환자를 위한 지속적인 혁신과 개인화된 치료를 추진하려는 회사의 의지를 강조합니다.
- 2021년 1월, Pfizer Inc.는 2020년 하반기에 Pfizer Breakthrough Growth Initiative(PBGI)의 일환으로 임상 단계의 바이오텍 기업 4곳에 총 1억 2,000만 달러를 투자했다고 발표했습니다. Pfizer는 다양한 바이오텍 기업에 약 5억 달러라는 막대한 금액을 투자하고 있습니다. 이 투자는 Pfizer가 미래의 전략적 이익을 위해 유망한 임상 개발 프로그램의 연속성을 보장하는 데 도움이 될 것입니다. 이는 회사가 신제품을 출시하고 혁신함으로써 사업을 확장하는 데 도움이 되었습니다.
협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략은 헌터 증후군 치료 시장에서 회사 시장을 강화하고 있으며, 이를 통해 조직이 헌터 증후군 치료 약물에 대한 제공을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SEVERITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 EMERGING TREATMENTS FOR HUNTER SYNDROME
5.1 TREATMENT: DNL310
5.2 TREATMENT: JR141
5.3 TREATMENT: TAK-609/SHP609/HGT-2310
5.4 TREATMENT: RGX-121
5.5 TREATMENT: SB-913
5.6 TREATMENT: AVR-RD-05
5.7 TREATMENT: ODIPARCIL
5.8 TREATMENT: AGT-181
5.9 TREATMENT: EGT-301
6 REGULATORY GUIDELINES FOR HUNTER SYNDROME (MPS II)
6.1 U.S REGULATORY FRAMEWORK FOR HUNTER SYNDROME
6.2 EUROPE REGULATORY FRAMEWORK FOR HUNTER SYNDROME
6.3 ASIA-PACIFIC REGULATORY FRAMEWORK FOR HUNTER SYNDROME
7 EPIDEMIOLOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF HUNTER SYNDROME
8.1.2 RISING ADOPTION OF GENE THERAPY
8.1.3 INCREASING GOVERNMENT INITIATIVES
8.1.4 INCREASING FUND BY PUBLIC AND PRIVATE ORGANISATIONS
8.1.5 TECHNOLOGICAL ADVANCEMENTS
8.2 RESTRAINTS
8.2.1 ADVERSE EFFECTS OF CURRENT TREATMENTS
8.2.2 STRINGENT GOVERNMENT REGULATIONS FOR MPS II TREATMENT DEVELOPMENT
8.2.3 UNAWARENESS AMONG PEOPLE OF THE EXISTENCE OF HUNTER SYNDROME
8.2.4 HIGH COST ASSOCIATED WITH TREATMENT OF MPS II
8.3 OPPORTUNITIES
8.3.1 HIGH DEMAND OF DISEASE-SPECIFIC TREATMENT
8.3.2 RISING COLLABORATIONS, AND MERGERS & ACQUISITIONS AMONG THE MARKET PLAYERS
8.3.3 PRESENCE OF NOVEL PIPELINE DRUGS
8.4 CHALLENGES
8.4.1 LIMITATIONS OF CURRENT TREATMENT
8.5 IMPROPER REIMBURSEMENT POLICIES
9 IMPACT OF COVID-19 ON THE ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY
10.1 OVERVIEW
10.2 MODERATE TO SEVERE
10.3 MILD TO MODERATE
11 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 ENZYME REPLACEMENT THERAPY
11.2.1 ELAPRASE + TAK-609
11.2.2 HUNTERASE
11.2.3 IZCARGO
11.3 STEM CELL TRANSPLANT
11.3.1 UMBILICAL CORD TRANSPLANT
11.3.2 BONE MARROW TRANSPLANT
11.4 SURGICAL TREATMENT
11.4.1 CARDIAC VALVE REPLACEMENT SURGERY
11.4.2 TRACHEOSTOMY
11.4.3 POSITIVE AIRWAY PRESSURE DEVICES
11.4.4 JOINT CONTRACTURES
11.4.5 ABDOMINAL HERNIA SURGERY
11.4.6 OTHERS
11.5 OTHERS
12 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS
12.1 OVERVIEW
12.2 RESPIRATORY DISORDERS
12.3 NEUROLOGICAL DISORDERS
12.4 CARDIOVASCULAR
12.5 MUSCULOSKELETAL
12.6 GASTROINTESTINAL DISORDERS
12.7 OPHTHALMIC
12.8 AUDIOLOGIC
12.9 DENTAL
12.1 OTHERS
13 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY REGION
15.1 ASIA-PACIFIC
15.1.1 JAPAN
15.1.2 SOUTH KOREA
15.1.3 CHINA
15.1.4 INDIA
15.1.5 AUSTRALIA
15.1.6 SINGAPORE
15.1.7 MALAYSIA
15.1.8 THAILAND
15.1.9 INDONESIA
15.1.10 PHILIPPINES
15.1.11 VIETNAM
15.1.12 REST OF ASIA-PACIFIC
16 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 GREEN CROSS CORP.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 ABBOTT
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENTS
18.4 AVROBIO, INC.
18.4.1 COMPANY SNAPSHOT
18.4.2 PRODUCT PORTFOLIO
18.4.3 RECENT DEVELOPMENTS
18.5 BD
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 CANBRIDGE LIFE SCIENCES LTD.
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 DENALI THERAPEUTICS
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 HOMOLOGY MEDICINES, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 TECHNOLOGY PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 INVENTIVA
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 JASPER THERAPEUTICS, INC.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 JCR PHARMACEUTICALS CO., LTD.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 JOHNSON & JOHNSONS SERVICES, INC.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 MEDTRONIC
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 NOVARTIS AG
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 ON-X LIFE TECHNOLOGIES (A SUBSIDIARY OF CRYOLIFE, INC.)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
18.16 PFIZER INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
18.17 REGENXBIO INC.
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 SANGAMO THERAPEUTICS
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 STRYKER
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENTS
18.2 UCB S.A.
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
표 목록
LIST OF TABLES
TABLE 1 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 2 ASIA-PACIFIC MODERATE TO SEVERE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 ASIA-PACIFIC MILD TO MODERATE IN ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC RESPIRATORY DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC NEUROLOGICAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC CARDIOVASCULAR IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC MUSCULOSKELETAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC GASTROINTESTINAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC OPHTHALMIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC AUDIOLOGIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC DENTAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
TABLE 23 ASIA-PACIFIC HOSPITALS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC CLINICS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOME HEALTHCARE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
TABLE 28 ASIA-PACIFIC HOSPITAL PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC RETAIL PHARMACY IN HUNTER SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC ONLINE PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 41 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 42 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 43 JAPAN ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 JAPAN STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 45 JAPAN SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 46 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 47 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 48 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 49 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 50 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 SOUTH KOREA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 SOUTH KOREA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 SOUTH KOREA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 55 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 56 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 57 CHINA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 58 CHINA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 CHINA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 CHINA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 CHINA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 CHINA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 63 CHINA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 CHINA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 INDIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 66 INDIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 INDIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 INDIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 INDIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 INDIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 71 INDIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 72 INDIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 73 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 74 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 AUSTRALIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 AUSTRALIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 AUSTRALIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 79 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 80 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 81 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 82 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 SINGAPORE ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 SINGAPORE STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 SINGAPORE SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 87 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 88 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 89 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 90 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 MALAYSIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 MALAYSIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 MALAYSIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 95 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 96 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 97 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 98 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 99 THAILAND ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 100 THAILAND STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 101 THAILAND SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 103 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 104 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 105 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 106 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 INDONESIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 INDONESIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 INDONESIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 111 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 112 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 113 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 114 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 PHILIPPINES ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 PHILIPPINES STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 117 PHILIPPINES SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 118 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 119 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 120 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 121 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 122 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 VIETNAM ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 124 VIETNAM STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 VIETNAM SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 127 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 128 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 129 REST OF ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
그림 목록
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
FIGURE 2 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : MARKET END USER COVERAGE GRID
FIGURE 9 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALANCE OF HUNTER SYNDROME IS EXPECTED TO DRIVE THE ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 MODERATE TO SEVERE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET
FIGURE 14 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 17 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
FIGURE 18 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 19 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 20 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 21 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 22 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 23 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028)
FIGURE 24 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.